Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN® and Cholesterol Absorption Inhibitor

Pivotal Therapeutics Inc [Pressemappe]
Woodbridge, Ontario (ots/PRNewswire) – Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), (“Pivotal” or the “Company”), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced that … Lesen Sie hier weiter…

Ähnliche Beiträge:

  • Pivotal Announces Publication of a Clinical Trial Showing…
  • Pivotal Therapeutics VASCAZEN®-REVEAL Trial Meets…
  • Scientific Data Supports Superiority of Pivotal’s…
  • Unique Vasoprotective and Antihypertensive Effects of…
  • Pivotal Announces Scientific Presentation at the 17th World…

Leave a reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>